B&K Precision: B&K Corp Seeks IPO To Keep Its Slow-Developing Drugs Alive

Key Takeaways: B&K lost nearly 200 million yuan in the past two years, as its administrative expenses exceeded its R&D spending The drug maker's president, who is also the founder's son, has previous experience mainly in the fields of intelligent and autonomous driving By Molly Wen read more